Growth Suppression of Human Hepatocellular Carcinoma Xenografts by a Monoclonal Antibody CH12 Directed to Epidermal Growth Factor Receptor Variant III
Open Access
- 1 February 2011
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (7), 5913-5920
- https://doi.org/10.1074/jbc.m110.192252
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Hepatocellular carcinoma: Current management and future trendsGastroenterology, 2004
- [Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma].2004
- Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the ReceptorJournal of Biological Chemistry, 2004
- Carcinogen-induced alteration in liver epidermal growth factor receptor distribution during the promotion stage of hepatocarcinogenesis in ratCancer Letters, 1997
- A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.1996
- Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.1995
- Cyclins and cancer II: Cyclin D and CDK inhibitors come of ageCell, 1994
- A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.Proceedings of the National Academy of Sciences, 1994
- Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma.1994
- Amplification and Overexpression of Cyclin D1 in Human Hepatocellular CarcinomaBiochemical and Biophysical Research Communications, 1993